Castle Biosciences Inc
NASDAQ:CSTL

Watchlist Manager
Castle Biosciences Inc Logo
Castle Biosciences Inc
NASDAQ:CSTL
Watchlist
Price: 29.81 USD 3.22% Market Closed
Market Cap: 835m USD
Have any thoughts about
Castle Biosciences Inc?
Write Note

Gross Margin
Castle Biosciences Inc

81.9%
Current
80%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
81.9%
=
Gross Profit
255.4m
/
Revenue
311.9m

Gross Margin Across Competitors

Country US
Market Cap 834m USD
Gross Margin
82%
Country US
Market Cap 91.8B USD
Gross Margin
11%
Country US
Market Cap 87.7B EUR
Gross Margin
11%
Country US
Market Cap 73B USD
Gross Margin
14%
Country DE
Market Cap 24.9B EUR
Gross Margin
25%
Country US
Market Cap 20.1B USD
Gross Margin
28%
Country DE
Market Cap 18.8B EUR
Gross Margin
24%
Country US
Market Cap 18.3B USD
Gross Margin
33%
Country US
Market Cap 13.7B USD
Gross Margin
33%
Country DE
Market Cap 12.4B EUR
Gross Margin
25%
Country AU
Market Cap 13.4B AUD
Gross Margin
84%
No Stocks Found

Castle Biosciences Inc
Glance View

Market Cap
834m USD
Industry
Health Care

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.

CSTL Intrinsic Value
31.49 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
81.9%
=
Gross Profit
255.4m
/
Revenue
311.9m
What is the Gross Margin of Castle Biosciences Inc?

Based on Castle Biosciences Inc's most recent financial statements, the company has Gross Margin of 81.9%.